The store will not work correctly when cookies are disabled.
2,6-bis[(3,3-dimethylbutan-2-yl)oxy]-1,3,5,7-tetrathia-4-platinaspiro[3.3]heptane
ID: ALA413296
Max Phase: Preclinical
Molecular Formula: C14H28O2PtS4
Molecular Weight: 551.72
Molecule Type: Small molecule
Associated Items:
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Properties
Molecular Weight: 551.72 | Molecular Weight (Monoisotopic): 551.0620 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
References
1. Friebolin W, Schilling G, Zöller M, Amtmann E.. (2004) Synthesis and structure-activity relationship of novel antitumoral platinum xanthate complexes., 47 (9): [PMID:15084124] [10.1021/jm0309405] |